Last $66.40 USD
Change Today -0.94 / -1.40%
Volume 1.0M
As of 8:10 PM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Steven C. Gilman Ph.D.

Chief Scientific Officer and Executive Vice President of Research & Development, Cubist Pharmaceuticals Inc.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 2 different organizations across 3 different industries.

See Board Relationships
61$2,109,958
As of Fiscal Year 2013

Background*

Dr. Steven C. Gilman, also known as Steve, Ph.D has been the Chief Scientific Officer of Cubist Pharmaceuticals Inc., since February 2008, and has been its Executive Vice President of Research & Development since September 2010. Dr. Gilman served as a Senior Vice President of Discovery & Non Clinical Development at Cubist Pharmaceuticals Inc. He has more than 25 years of drug research and development experience. Previously, he served as Chairman of the Board of ActivBiotics, ...

Read Full Background

Corporate Headquarters*

65 Hayden Avenue
Lexington, Massachusetts 02421

United States

Phone: 781-860-8660
Fax: --

Board Members Memberships*

Director
2004-Present
Chairman and Chief Executive Officer

Education*

MS
Pennsylvania State University
PhD
Pennsylvania State University
BA
Miami University

Other Affiliations*

Annual Compensation*

Salary$475,000
Total Annual Compensation$475,000

Stock Options*

Restricted Stock Awards$649,958
All Other Compensation$16,946
Exercised Options30,125
Exercised Options Value$935,104
Exercisable Options216,659
Exercisable Options Value$8,828,983
Unexercisable Options127,317
Unexercisable Options Value$3,984,687
Total Value of Options$13,748,774
Total Number of Options374,101

Total Compensation*

Total Annual Cash Compensation$810,006
Total Short Term Compensation$475,000
Other Long Term Compensation$666,904
Total Calculated Compensation$2,109,958
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CBST:US $66.40 USD -0.94

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President and Director
Theravance Inc.
$515.4K
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Carolyn J. Logan Chief Executive Officer, President and Director
Salix Pharmaceuticals Ltd.
$867.5K
Eduardo Javier Sanchiz Yrazu Chief Executive Officer, Member of Management Board, Chief Executive of Corporate Development & Finance, Executive Director and Member of Compliance Committee
Almirall, S.A.
--
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CUBIST PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.